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Abstract Adhesion molecules such as vascular cell adhesion
molecule-1 (VCAM-1) play an important role during the early
stages of atherogenesis. Agastache rugosa has an anti-athero-
genic effect in low density lipoprotein receptor 3/3 mice.
Moreover, A. rugosa reduced macrophage infiltration and
VCAM-1 expression has been localized in aortic endothelium
that overlies early foam cell lesions. This study ascertained that
tilianin (100 WM), a major component of A. rugosa, inhibits the
tumor necrotic factor-K (TNF-K)-induced expression of VCAM-
1 by 74% in cultured human umbilical vein endothelial cells
(HUVECs). Also, tilianin (100 WM) reduced TNF-K-induced
activation of nuclear factor-UB in HUVECs. ß 2001 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
The adhesion of monocytes to the vascular endothelium
and their subsequent recruitment into the artery wall are
key features in the pathogenesis of atherosclerosis [1,2]. Vas-
cular cell adhesion molecule-1 (VCAM-1), an adhesion mole-
cule expressed on the endothelial cell surface, may be partly
responsible for the recruitment of monocytes during athero-
genesis [3^5]. VCAM-1 expression has been demonstrated in
human coronary atherosclerotic plaques, and this is consistent
with the belief that this adhesion molecule plays a role in the
disease [6,7].
Nuclear factor-UB (NF-UB) is a heterodimer of two pro-
teins, p50 and p65, that are localized in the cytoplasm of un-
stimulated cells in an inactive form [8]. On stimulation of cells,
for example by tumor necrotic factor-K (TNF-K), the hetero-
dimer translocates to the nucleus and transactivates gene ex-
pression [8,9]. The VCAM-1 promoter consists of two NF-UB
binding sites [10]. The cell-surface expression of VCAM-1
correlates with an increase in mRNA levels, which indicates
transcriptional activation of this gene by TNF-K. Flavonoids,
such as PD 098063 (2-(3-amino-phenyl)-8-methoxy-chromene-
4-one), and gallates, have been shown to block the TNF-K-
stimulated NF-UB activation, transcription, and cell-surface
expression of VCAM-1 in endothelial cells [11^13].
The plant species Agastache rugosa (Labiatae) contains sev-
eral kinds of £avonoids (acacetin-7-O-L-D-glucopyranoside (ti-
lianin), acacetin, linarin, and agastachoside) [14,15], and tilia-
nin is a main constituent of A. rugosa. Both the extract and
the constituents of this plant have a variety of physiological
and pharmacological activities on in£ammatory immune re-
sponses such as anti-complement [16], and the inhibition of
Haemophilus in£uenzae adhesion to human cells [17].
In the present study, we investigated the e¡ect of A. rugosa
on the atherosclerosis, a chronic in£ammatory disease [1], us-
ing low density lipoprotein receptor de¢cient (Ldlr3/3) mice.
To gain some insight into the potential molecular mechanisms
of the anti-atherosclerotic properties of A. rugosa, the inves-
tigation was extended to examine the e¡ect of tilianin on
TNF-induced VCAM-1 expression in endothelial cells, an
early step in the pathophysiology of atherosclerosis.
2. Materials and methods
2.1. A. rugosa extract and tilianin
The extract (2.5 kg) was obtained by extracting the aerial parts of
A. rugosa (30 kg) three times with methanol (120 l). It was then
suspended in H2O and partitioned with n-hexane, chloroform, and
n-butanol, sequentially, and the chloroform fraction (590 g) was sub-
ject to column chromatography on silica gel (230^400 mesh, 20U75
cm, Merck, USA) using a chloroform^methanol mixture (10:1, v/v) to
give ¢ve fractions. Tilianin (49.5 g) was obtained as a pale yellow
precipitate in methanol from the fourth fraction (Fig. 1).
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Fig. 1. Structure of tilianin.
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2.2. Animals and blood chemical analysis
Three breeding pairs of homozygous Ldlr-null (B6,129-Ldlrtm1Her
3/3) mice [18] were purchased from the Jackson Laboratory (ME,
USA), and bred at the Korea Research Institute of Bioscience and
Biotechnology under speci¢c pathogen free conditions. Twenty female
Ldlr3/3 mice were randomly divided into two groups of 10 animals
and fed on a high cholesterol diet (CRF-1 supplemented with 15% fat,
1.25% cholesterol, and 0.5% Na-cholate, Oriental Yeast Co. Ltd.,
Japan), the ¢rst group without additional supplementation (control),
and the second group supplemented with 1% (weight/diet weight
(w/w)) of the methanol extract of A. rugosa. The mice had ad libitum
access to water and food. Following treatment with extract for
8 weeks, the mice were sacri¢ced by cervical dislocation, and plasma
total cholesterol was measured using an automatic blood chemical
analyzer (CIBA Corning, OH, USA). Lipoprotein fractions were sep-
arated by FPLC from the pooled plasma of each group [19].
2.3. Quanti¢cation of aortic sinus lesions and immunohistochemical
analysis of VCAM-1 and macrophage
Fatty streak lesions were quanti¢ed by evaluating the lesion size in
the aortic sinus, as previously described [20], with minor modi¢ca-
tions. Atherosclerotic plaque was stained with Oil red O and coun-
ter-stained with Harris hematoxylin. The lesion area was then quan-
ti¢ed by computer-assisted morphometry (Image pro plus, MD, USA)
and the average lesion size calculated for each animal. Frozen sections
were stained with a rat monoclonal antibody to mouse macrophages
(MOMA-2, Serotec Inc., NC, USA) and a rabbit anti-mouse poly-
clonal VCAM-1 antibody (diluted 1:100, Santa Cruz Biotechnology,
CA, USA) using the ABC method (Novastatin Super ABC kit, No-
vocastra Lab. Ltd., UK). Macrophage in¢ltration was quanti¢ed by
determining the MOMA-2-stained area [21]. The sections stained with
VCAM-1 antibody were evaluated with light microscopy and graded
by two independent observers, each of whom was blinded to the
identity of the sections. Staining intensity was scored semi-quantita-
tively [22] : 0 indicated no staining; 1, rare positive cells or staining
barely visible at low power (U100); 2, focal staining or faint di¡use
staining clearly visible at low power; 3, multifocal staining or moder-
ate di¡use staining; and 4, intense di¡use staining. The scores of the
two observers were highly correlated (r2 = 0.96; P6 0.0001). For con-
venience, therefore, scores from only one observer were used for cal-
culation of vessel mean scores.
2.4. Flowcytometry analysis of VCAM-1
Following treatment of human umbilical vein endothelial cells
(HUVECs) with tilianin, the cells were trypsinized, collected in tubes,
and washed three times with phosphate-bu¡ered saline (PBS). The
cells (5U105) were then resuspended in 100 Wl of PBS, and mouse
anti-human monoclonal antibody (Rb 1/9; 1 Wg) added, whilst the
tubes were continuously shaken for 40 min on ice. The cells were
then washed three times with cold PBS and incubated with FITC-
Fig. 2. E¡ect of A. rugosa extract on atherosclerotic lesions in
Ldlr3/3 mice fed a cholesterol diet for 8 weeks. Representative
cross sections of aortic valves (U100) in hearts from (A) a control
group and (B) a 1% (w/w) extract-treated group. (C) Oil red O-
stained aortic valve lesion areas were quanti¢ed by computer-associ-
ated morphometry. All results are shown as mean þ S.D., n = 8.
Fig. 3. Plasma lipoprotein cholesterol distribution in Ldlr3/3 mice
fed a 1% (w/w) methanol extract of A. rugosa. Plasma was obtained
from Ldlr3/3 mice 8 weeks after the administration of 1% (w/w)
MeOH extract of A. rugosa. Equal volumes of plasma from 10 ani-
mals were pooled, and lipoproteins were size-fractionated by FPLC
using a Superose 6 HR column. Total cholesterol content of each
fraction (1 ml/fraction) was measured using enzymatic colorimetric
method kits (Sigma Chemical Co.) according to the manufacturer’s
instructions. The retention times for mouse VLDL (d6 1.006 g/ml),
IDL/LDL (d = 1.02^1.055 g/ml) and HDL (d = 1.07^1.21 g/ml) are
indicated.
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conjugated goat F(abP)2 anti-mouse IgG at a dilution of 1:25 in PBS
for 1 h in ice. The cells were then ¢xed with 1% paraformaldehyde
and analyzed by FACScan (Bio-Rad, USA) analysis. Results were
plotted as £uorescence intensity vs. cell numbers.
2.5. Electrophoretic mobility shift assay (EMSA)
HUVECs were maintained in a EGM-2 Bullet kit (Clonetics, Bio-
Whittaker, Inc., MD, USA), and pre-incubated with 1, 10, and 100
WM of tilianin for 2 h. After pre-incubation, HUVECs were activated
by 10 ng/ml of TNF-K for 15 min in the presence of tilianin. Nuclear
protein (10 Wg) was mixed with a double-stranded oligonucleotide (5
pM) corresponding to the NF-UB/Rel [23] binding sequence. The 5 Wg
of nuclear protein was incubated with 2 Wl of radio-labeled probe
(20 000 cpm) to make the protein^DNA complex.
2.6. Statistics
Results are expressed as mean þ S.D. and statistical signi¢cance was
determined using Student’s t-test.
Fig. 4. Quantitative analysis of macrophage content and VCAM-1 in the aortic arteries of Ldlr3/3 mice fed a 1% (w/w) methanol extract of
A. rugosa. A^D: Immunohistochemical staining of aortic valve lesions (U200) with the macrophage marker MOMA-2 (A, C) and VCAM-1
antibody (B, D). Representative frozen sections from the aortic arches of Ldlr3/3 mice fed a high cholesterol diet (A, B) and 1% (w/w) ex-
tract-supplemented high cholesterol diet (C, D). E: Quantitative analysis of macrophage in¢ltrating area. The area of MOMA-2 staining was
determined by computer-associated morphometry. All results are shown as mean þ S.D., n = 8. F: Intensity of histochemical staining for detec-
tion of VCAM-1 expression. See Section 2 for description of 0^4 intensity scales. Each data point represents a single artery. Bars indicate the
group medians.
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3. Results
3.1. Analysis of atherosclerotic lesion
Fig. 2 shows sections of aortic roots from Ldlr3/3 mice in
the two groups that showed oil-red O positive atherosclerotic
lesions on light microscopic examination (Fig. 2A,B). The
aortic sinus of the control group showed lipid-enriched
foam cells in the vessel walls and an increased amount of
extracellular matrix in the presence of sheaths apparently
composed of proliferative smooth muscle cells. However, the
lesions in the 1% extract-supplemented group were smaller
and less advanced, and these were characterized by a less
prominent necrotic core and less smooth muscle cell prolifer-
ation. Computer-associated morphometry was used to quan-
tify lesion areas. The mean lesion area of the aortic sinus was
signi¢cantly reduced in the 1% extract-supplemented group
compared with the control group (162 629.6 þ 28 362.1 Wm2
vs. 304 644.0 þ 76 602.6 Wm2, P6 0.01) (Fig. 2C).
3.2. E¡ects of tilianin on plasma lipoprotein pro¢les
Following the 8 weeks high cholesterol diet, plasma choles-
terol levels were markedly elevated, and about 3.5 times that
of the chow diet-fed Ldlr3/3 mice. Total plasma cholesterol
levels were reduced slightly (1064.6 þ 31.5 mg/dl vs.
985.6 þ 14.7 mg/dl) after treatment with A. rugosa extract,
and the cholesterol content of VLDL was also lower in the
A. rugosa extract-supplemented group, however, this was not
statistically signi¢cant (Fig. 3).
3.3. Immunohistochemical staining of VCAM-1 and
macrophages
The mechanism of the anti-atherogenic e¡ect of the extract
is likely to involve recruitment of monocyte into the arterial
wall. To evaluate this possibility, macrophage accumulation
and VCAM-1 expression in the aortic arch were examined by
immunohistochemical staining with speci¢c antibodies. A
marked accumulation of the macrophages was observed in
the subendothelial surface of the control group (Fig. 4A),
and this accumulation was reduced in the 1% extract-treated
group (Fig. 4C). Aortic arches from 1% extract-treated mice
had 37% less MOMA-2 staining than arches from control
group (88 561.5 þ 9403.5 Wm2 vs. 131 497.3 þ 35 611.1 Wm2,
P6 0.05) (Fig. 4E). The fact that VCAM-1 expression plays
an important role in monocyte recruitment, was evident from
the VCAM-1 expression levels in endothelial cells at the edges
of and adjacent to the lesions (Fig. 4B). The expression of
VCAM-1 was reduced in all aortic arches from the 1% ex-
tract-treated group (Fig. 4D,F).
3.4. E¡ects of tilianin on the expression of VCAM-1 and
NF-UB activation
Fig. 5 shows the representative traces of FACS analysis
from three separate analyses. To examine whether tilianin
reduced the elevated expression of VCAM-1 on HUVECs
induced by TNF-K, FACS analysis was conducted using
VCAM-1 speci¢c monoclonal antibody (PharMingen, Becton
Dickinson, USA). Pretreatment of HUVECs with tilianin
markedly suppressed the TNF-K-induced expression of
VCAM-1 in a dose-dependent manner. The TNF-K-induced
expression of VCAM-1 was reduced by 10 and 100 WM of
tilianin, by 80 and 74%, respectively. Also, both the extract
and tilianin inhibited the VCAM-1 mRNA expression induced
by TNF-K assessed by RT-PCR (data not shown).
To determine whether tilianin inhibits activation of NF-UB,
the e¡ect of tilianin on NF-UB activation in HUVECs was
evaluated by EMSA. The activity of NF-UB was markedly
suppressed by the tilianin treatment (100 WM) (Fig. 6A).
The identity of the activated NF-UB/oligonucleotide complex
in HUVECs was determined by supershift analysis (Fig. 6B).
The addition of p65 and/or p50 antiserum during NF-UB/oli-
gonucleotide binding resulted in a shift of the complex in ac-
cordance with the ¢ndings of a previous study [24]. In the
competitive assay, the cold identical oligonucleotide sequences
inhibited labeled oligonucleotide binding, whereas the mutant
sequences did not inhibit this speci¢c binding. Hence, NF-UB
activation in response to TNF-K conclusively resembles that
of the p50/p65 heterodimer NF-UB complex.
4. Discussion
In this study, we investigated the anti-atherogenic activity
of A. rugosa extract in vivo. The extract of A. rugosa has been
shown previously to show a range of activities upon in£am-
matory immune responses [16,17] and inhibitory activity on
the expression VCAM-1. A. rugosa is known to contain a
number of £avonoids, such as tilianin, acacetin, and diosme-
tin, which have shown inhibition activity against the expres-
sion of cellular adhesion molecules on the surface of THP-1
leukemic monocyte cells. Among the £avonoids of A. rugosa,
tilianin was a major constituent (1.96% of the methanol ex-
tract), and showed a strong inhibitory activity on the TNF-K-
induced expression of adhesion molecules in the THP-1 cells
(data not shown). This information was based on our pre-
vious studies upon the anti-atherogenic mechanism of A. ru-
gosa in vitro.
The present study is the ¢rst to investigate the e¡ect of
A. rugosa extract on the development of vascular proliferative
disease in vivo. Fatty streak formation was prevented, to a
statistically signi¢cant degree, in high-cholesterol dieted
Ldlr3/3 mice after treatment with the extract for 8 weeks.
The pattern of the lipoprotein cholesterol pro¢le was similar
to that reported in previous studies [18,25]. The cholesterol
pro¢le of VLDL di¡ered slightly in the two groups, as the
Fig. 5. Dose-dependent e¡ect of tilianin on endothelial adhesion
molecule induction. HUVECs were pre-incubated with 10 or 100
WM for 2 h and stimulated with TNF-K (10 ng/ml, 16 h), stained
for VCAM-1 or isotype control, and analyzed by £ow cytometry.
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total cholesterol was slightly reduced in the extract-treated
group. Thus, these lowered plasma cholesterol levels by
A. rugosa extract may help to protect against atherosclerosis.
Decreased plasma VLDL levels in animals could have been
the result of either decreased hepatic secretion of VLDL par-
ticles or increased clearance. The increment of body weight
and consumption of the diet were similar in the extract-treated
and control animals (data not shown), which excludes any
negative e¡ect of the extract on appetite.
Endothelial cell VCAM-1 expression patterns were highly
reproducible and similar in rabbits and Ldlr3/3 mice fed a
high cholesterol diet [26]. Biohumoral correlation studies have
shown a signi¢cant positive association between increasing
plasma concentrations of soluble VCAM-1 and the risk of
atherosclerosis [27,28]. Our present study shows that the ex-
pression of VCAM-1 and accumulation of macrophages in the
lesions were regressed by A. rugosa extract treatment.
To determine the possible mechanisms of the anti-athero-
genic e¡ect of A. rugosa, the £avonoid tilianin, a major com-
ponent of the methanoic extract of the aerial portion of
A. rugosa, was investigated. Other naturally occurring £avo-
noids, including gallates [13], apigenin [29], and PD098063
[12], belong to another group of phenolic compounds that
seem to inhibit monocyte adhesion by a variety of mecha-
nisms. Apigenin suppressed cytokine-induced VCAM-1 ex-
pression by inhibiting NF-UB activation without a¡ecting
the nuclear translocation of NF-UB p65 [29]. PD098063 selec-
tively inhibited VCAM-1 expression by a mechanism inde-
pendent of NF-UB, and without altering cytokine-induced
ICAM-1 expression [12]. Gallates inhibited the cytokine-in-
duced nuclear translocation of NF-UB and the expression of
leukocyte adhesion molecules in HUVECs [13]. In accordance
with studies on gallates, tilianin inhibits TNF-K-induced
VCAM-1 expression with FACS analysis, and also inhibits
TNF-K-induced NF-UB activation. Further studies on the ef-
fects of tilianin in vivo may extend the possible actions of
tilianin on the prevention of atherosclerosis by the inhibition
of NF-UB-dependent pro-atherogenic gene expression.
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